Compare BioNano Genomics Inc (BNGO) vs CSX Corporation (CSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs CSX Corporation — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while CSX Corporation trades at $50.02 (market cap $92.55B). The key difference: CSX Corporation is far larger — about 6775.3× BioNano Genomics Inc's market cap, and CSX Corporation pays a 1.12% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | CSX | |
|---|---|---|
Market Cap | $13.66M | $92.55B |
Sector | Health | Industrials |
52-Week High | $4.92 | $53.21 |
52-Week Low | $1.06 | $32.05 |
Enterprise Value | $16.26M | $110.52B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
CSX trades at $50.08, down slightly by 0.09% today, with a neutral technical signal despite bullish moving averages. The railroad operator posted strong Q2 2026 results with EPS of $0.54 beating estimates by 4.2% and revenue growth of 10%, driving improved investor sentiment. Valuation metrics show a P/E of 29.05 and P/S of 6.41, while profitability remains solid with 22.21% net margins and 24.37% ROE. Recent news highlights volume growth and margin expansion as key catalysts.
CSX demonstrates operational strength with consecutive earnings beats and raised 2026 guidance, supported by intermodal demand and cost controls. However, declining revenue trends from $14.9B in 2022 to $14.1B in 2025 and high debt levels pose risks. Analyst consensus is bullish with a $52.57 price target (4.9% upside), though competitive pressures and fuel costs require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
